January 2013: European Litigation Update

by Quinn Emanuel Urquhart & Sullivan, LLP
Contact

The European Court of Justice (ECJ) on European Supplementary Protection Certificate (SPC) for Further Medical Uses: With a remarkable ruling from July 2012 (Neurim Pharmaceuticals, C-130/11), the European Court of Justice (ECJ) substantiated its interpretation of the granting conditions for the European Supplementary Protection Certificate (SPC) for medicinal products by extending the scope of protection to usage patents. This judgment further liberalizes the SPC system and subsequently will stimulate investments of pharmaceutical or biotech companies researching on new medical uses of earlier marketed products.

General Background on the SPC: Subject to European regulations complemented by national legislation, e.g. by section 16a of the German Patent Act, the SPC generally allows for supplementary protection of patents for products depending on regulatory licensing. The SPC provides a maximum of an additional five years of protection to compensate the patent owner for the loss of time for effective use due to the period that elapses between the filing of an application for a patent for a new product and the authorization to place the product on the market. Within European legislation, the lack of effective protection has been considered to penalize research, potentially leading to a relocation of research centers situated in the Member States to countries that offer greater protection. In view of the purpose of promoting protection for research, the SPC so far has been introduced by European regulations for medicinal products and for plant protection products such as herbicides and insecticides. By virtue of the direct effect of European regulations, the granting conditions are thereby governed by European Law, being subject to the jurisdiction of the European Court of Justice (ECJ).

The Neurim Case: In the recent decision Neurim Pharmaceuticals, the ECJ inter alia had to substantiate its interpretation of Regulation (EC) No 469/2009 concerning the SPC for medicinal products. The referring UK court first and foremost was seeking clarification on the requirement pursuant to Article 3(d) of the Regulation that the marketing authorization referred to in the SPC application has to be the first authorization to market as a medicinal product.

The case concerned Neurim’s discovery that appropriate formulations of the natural hormone melatonin could be used as a medicine for insomnia. Based on a patent protecting a medical product for human use called “Circadin”, Neurim applied for a grant of an SPC. This application was rejected by the UK Intellectual Property Office as being contrary to Article 3(d) of the Regulation, since an earlier marketing authorization already had been granted for a medical use of melatonin with respect to regulating the seasonal breeding activity of sheep under the mark “Regulin”.

ECJ Ruling: The Court followed the opinion of the Advocate General and decided that the mere existence of an earlier marketing authorization obtained for a veterinary medicinal product does not preclude the grant of a SPC for a different application of the same product for which marketing authorization has been granted, provided that the application is within the limits of the protection conferred by the basic patent relied upon for the purposes of the application for the SPC. Furthermore, Article 13 (1), defining the duration of the SPC, equally must be interpreted as meaning that it refers to the marketing authorization of a product that comes within the limits of the protection conferred by the basic patent relied upon for the purposes of the SPC application.

The reasoning is formal and logical, as it is not only based on the wording and context of the Regulation, but also on its protective purpose, as the introduction of SPC was meant to foster research within the Member States, by preventing a relocation of research centers due to a lack of adequate protection. In these premises, the decision rightly broadens the application range of SPCs by including usage patents for new medical developments of earlier known medicinal products in the scope of supplementary protection.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Quinn Emanuel Urquhart & Sullivan, LLP | Attorney Advertising

Written by:

Quinn Emanuel Urquhart & Sullivan, LLP
Contact
more
less

Quinn Emanuel Urquhart & Sullivan, LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.